Skip to main content
  • Book
  • © 2007

Entry Inhibitors in HIV Therapy

Birkhäuser
  • The impact of viral sequence diversity on this class of inhibitors is discussed

  • Connection between basic research and clinical studies is shown

  • Focuses on real-world issues, such as virus phenotyping in the clinic

  • Unique collection of contributors from basic research, pharmaceutical research, and the clinic

  • Includes supplementary material: sn.pub/extras

Part of the book series: Milestones in Drug Therapy (MDT)

Buy it now

Buying options

eBook USD 129.00
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book USD 169.99
Price excludes VAT (Canada)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

This is a preview of subscription content, log in via an institution to check for access.

Table of contents (12 chapters)

  1. Front Matter

    Pages I-X
  2. The challenge of HIV sequence diversity in the envelope glycoprotein

    • Laurence Vergne, Martine Peeters
    Pages 17-29
  3. Attachment of human immunodeficiency virus to cells and its inhibition

    • Stefan Pöhlmann, Michel J. Tremblay
    Pages 31-47
  4. Inhibitors that target gp120-CD4 interactions

    • Pin-fang Lin, John Kadow, Louis Alexander
    Pages 49-62
  5. Inhibitors that target gp120 interactions with coreceptor

    • Julie M. Strizki, Donald E. Mosier
    Pages 63-78
  6. Inhibitors that target fusion

    • Wei Wang, Carol D. Weiss
    Pages 79-97
  7. HIV-1 entry inhibitors as microbicides

    • Clyde E. Hart, Tammy Evans-Strickfaden
    Pages 99-117
  8. Entry inhibition of HIV-1 subtype C isolates

    • Lynn Morris, Mia Coetzer, Elin S. Gray, Tonie Cilliers, Kabamba B. Alexandre, Penny L. Moore et al.
    Pages 119-131
  9. Future clinical prospects for entry inhibitors

    • Sonya L. Heath, J. Michael Kilby
    Pages 145-160
  10. Enfuvirtide: from basic science to FDA approval

    • Michael L. Greenberg
    Pages 161-177
  11. Back Matter

    Pages 197-200

About this book

Entry Inhibitors in HIV Therapy details the current status of this relatively new and very dynamic class of inhibitors, appealing to both the clinician and basic research scientist. A unique overview of obstacles and accomplishments is presented. The book features chapters that explain the challenges of high sequence diversity in the viral envelope gene for the development and use of entry inhibitors, the clinical utility of virus phenotyping, the development of this class of inhibitors as microbicidal therapy, and the success story of enfuvirtide from the bench to FDA approval. Both basic research findings and results of clinical studies are covered and linked together by a diverse panel of experts in the field.

Editors and Affiliations

  • Monogram Biosciences, South San Francisco, USA

    Jacqueline D. Reeves

  • Department of Pathology and Laboratory Medicine, Emory Vaccine Center, Emory University, Atlanta, USA

    Cynthia A. Derdeyn

Bibliographic Information

Buy it now

Buying options

eBook USD 129.00
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book USD 169.99
Price excludes VAT (Canada)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access